Search the Newsreel

Edesa Biotech Q3 Results: EPS misses estimate, losses widen 140% YoY

Edesa Biotech (EDSA) loss widens to $11.9M as R&D surges and cash tightens

Edesa Reports $5.4 Million Q3 Loss as EB06 Phase 2 Site Activation Begins

Edesa Biotech (EDSA) reported a net loss of $5.4 million for Q3 2026, an increase from $1.7 million in the prior year, primarily due to rising operating expenses from its Phase 2 EB06 vitiligo study. The company is beginning site activation for this study …

Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results

Edesa Biotech (Nasdaq: EDSA) reported its fiscal third-quarter 2026 results, showing a net loss of $5.4 million due to increased operating expenses. The company announced it has completed preparations for its Phase 2 EB06 vitiligo trial and begun activating initial investigational sites, with patient …

Edesa Biotech (EDSA) to Post Earnings on Monday

Edesa Biotech (EDSA) is scheduled to release its quarterly earnings after market close on Monday, August 10th, with analysts anticipating a loss of $0.435 per share. The company previously missed estimates with a loss of $0.49 per share. Despite mixed analyst opinions, MarketBeat reports …

Edesa Biotech Inc (EDSA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Edesa Biotech Inc (EDSA) has an earnings forecast score of 8.00, ranking 169th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $9.00, with a high of $19.00 and a low of $5.00, and predominantly recommend a "Buy" …

Edesa Biotech (NASDAQ: EDSA) CEO receives 5,324 restricted share units

Edesa Biotech's CEO, Pardeep Nijhawan, was granted 5,324 restricted share units on August 3, 2026, which vested immediately under the company's 2019 Equity Incentive Compensation Plan. Following this grant, Nijhawan directly holds 893,386 common shares, in addition to significant indirect holdings through various affiliated …

Endesa, S.A. acaba de superar las previsiones de los analistas, y estos han ido revisando al alza sus previsiones

Endesa SA (ELEZF) (Q2 2026) Earnings Call Highlights: Strong Financial Performance Amid Market ...

This article first appeared on GuruFocus. EBITDA: Increased by 20% to EUR 3.2 billion. Net Income: Rose by 41% to EUR 1.5 billion. EPS: Increased by 46% to EUR 1.44 per share. Cash Flow: EBITDA to FFO at 70%; FFO to net financial debt …

Las acciones de Endesa se disparan: claves de los resultados

HECHOS RELEVANTES.-ENDESA, S.A. Presentación de Resultados Primer Semestre 2026

Edesa Biotech Inc (EDSA) Institutional Confidence

Edesa Biotech Inc's (EDSA) institutional shareholding score is 3.00, placing it 192nd out of 385 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 52.45% quarter-over-quarter to 49.07%. Steven Cohen is the largest institutional shareholder, holding 1.31 shares.

EDSA|Edesa Biotech Inc|Price:4.680|Chg%:-0.290

This article provides a comprehensive stock analysis of Edesa Biotech Inc (EDSA) from TradingKey, highlighting its strong fundamentals and high growth potential. EDSA is currently valued at $5.430, with analysts giving it a "Buy" rating and a target price of $15.00. The company's clinical …

Edesa Biotech Inc (EDSA) Valuation: PE, PB & Fair Value Analysis

Edesa Biotech Inc (EDSA) currently has a valuation score of 6.60, placing it in the lower quartile of the Biotechnology & Medical Research industry. Its P/E ratio is -4.10, which is significantly below its recent high but above its recent low. Key valuation metrics …

Edesa Biotech Inc (EDSA) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Edesa Biotech Inc (EDSA), listing major shareholders by proportion, categorizing shareholder types, and providing a historical overview of institutional shareholdings. Key entities like Velan Capital Investment Management and Rubric Capital Management are identified as significant holders, alongside …

Edesa Biotech Market Sentiment

This article provides an overview of market sentiment for Edesa Biotech (EDSA), focusing on analyst consensus, short interest, options flow, and insider activity. It highlights that analysts have a "Buy" consensus with a significant upside to the average price target, while short interest is …

Edesa Biotech, Inc. Revenue Breakdown – NASDAQ:EDSA

This article focuses on Edesa Biotech, Inc. (NASDAQ: EDSA), providing a revenue breakdown accessible through TradingView. It highlights the availability of financial data, including statements, statistics, dividends, earnings, and segment performance, for the pharmaceutical company. The content primarily serves as a gateway to financial …

Edesa Biotech (EDSA) Revenue Breakdown - Main Composition

The article "Edesa Biotech (EDSA) Revenue Breakdown - Main Composition" is currently empty, as indicated by the content saying "Document". There is no specific information available about Edesa Biotech's revenue breakdown or financial composition in this document.

Las acciones de Endesa celebran unos buenos resultados

Endesa, S.A.: Historial y previsiones de dividendos

Endesa, S.A. : Consenso de Precios Objetivo y Recomendaciones de los Analistas | ELE | ES0130670112

Desa Deri Sanayi ve Ticaret AS (DESA) Forumu